Search Technologies

Researchers at the National Cancer Institute have developed a glypican-1 (GPC1) chimeric antigen receptor (CAR)-T cells using short immunoglobin subclass 4 (IgG4) hinge sequences that are highly potent against GPC1-expressing tumors. NCI seeks research co-development partners and/or licensees to advance the development of GPC1-IgG4 hinge CARs for the treatment of pancreatic cancer and other GPC1-expressing tumors.

Antibodies that specifically recognize and bind to the unshed portion (“stalk”) of human mesothelin are strong therapeutic candidates because they maintain contact with the cancer cell for a longer duration than other anti-mesothelin antibodies that are currently available. The National Cancer Institute (NCI) has developed such antibodies that specifically recognize and bind to the stalk of human mesothelin with high affinity. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.